AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...
AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca’s experimental ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate to fall short of ...
(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy ...
AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year ...
May 2026Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial ...
AstraZeneca Dividend 2026: The company reported revenue of Rs 579 Cr in Q4 FY26, compared to Rs 480 Cr in Q4 FY25, ...
NDTV Profit on MSN
AstraZeneca Pharma Q4 results: Profit down 23%, revenue rises
For the entire FY26, AstraZeneca's net profit jumped 62% to Rs 187.52 crore.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results